• Codexis Inc., of Redwood City, Calif., is using its CodeEvolver directed evolution technology in a collaboration with Merck & Co. Inc., of Whitehouse Station, N.J., to develop a highly efficient, cost-effective, enzyme-based production method for an intermediate used in boceprevir, the active ingredient in Merck's hepatitis C drug Victrelis.